SCHEDULE: Forbion Group Discloses 9.99% Stake in Vor Biopharma

Forbion Growth III entities have disclosed a 9.99% beneficial ownership stake in Vor Biopharma Inc. through pre-funded warrants.

Summary

• ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. (collectively 'Reporting Persons') have filed a Schedule 13G.
• The filing reports beneficial ownership of 9.99% of Vor Biopharma Inc.'s Common Stock.
• This ownership stems from pre-funded warrants to purchase up to 7,000,000 shares, acquired by ForGrowth III PA B.V. on June 27, 2025.
• The warrants have an exercise price of $0.002 per share.
• The warrants became exercisable on September 18, 2025, following the satisfaction of certain material conditions.
• Exercisability is subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock to be outstanding immediately after giving effect to the issuance of the shares issuable upon exercise.
• The Reporting Persons disclaim membership in a group for purposes of the Securities Exchange Act of 1934, as amended, despite making a single, joint filing.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Vor Biopharma Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% stake by a specialized growth fund like Forbion is generally a positive signal, indicating institutional confidence in Vor Biopharma. While the filing itself is purely factual, the underlying investment decision suggests a favorable view from a sophisticated investor.

Positives

• A significant institutional investor, Forbion Growth III, has taken a substantial stake in Vor Biopharma, potentially signaling confidence in the company's long-term prospects.
• The acquisition of 7,000,000 shares through warrants at an exercise price of $0.002 per share indicates a strategic investment at a potentially favorable entry point.

Negatives

• The beneficial ownership limitation of 9.99% means that some warrants are not immediately exercisable, potentially limiting the investor's immediate influence or full realization of their investment.

Risks

• The actual number of shares beneficially owned by the Reporting Persons is currently less than the full 7,000,000 due to the 9.99% beneficial ownership limitation.
• The exercisability of the warrants was contingent on 'certain material conditions beyond the control of the Reporting Persons,' implying potential external factors that could have affected or could still affect the full exercise.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from Vor Biopharma Inc. or the Reporting Persons regarding the company's future performance or strategic direction, beyond the future exercisability of warrants.

Industry Context

This filing indicates continued institutional investor interest in the biopharma sector, specifically in companies like Vor Biopharma. Large stakes by specialized growth funds like Forbion often suggest a belief in the long-term potential of the underlying technology or pipeline, aligning with trends of venture capital and private equity flowing into innovative life sciences companies.

Comparison to Industry Standards

• This is a standard Schedule 13G filing for disclosing a passive ownership stake above 5%.
• The 9.99% beneficial ownership limit is a common threshold used by investors to avoid triggering more stringent reporting requirements (e.g., Schedule 13D) or certain corporate governance implications.
• Forbion Growth III is a European life sciences venture capital firm, and their investment in a US-listed biopharma company like Vor Biopharma is consistent with cross-border investment trends in the biotech industry, where specialized funds seek promising assets globally.

Stakeholder Impact

• Shareholders: Existing shareholders may view the entry of a significant institutional investor as a positive endorsement, potentially increasing confidence and attracting further investment.
• Company Management: The company now has a large, potentially influential, institutional shareholder whose interests will need to be considered in strategic decisions.

Next Steps

• Vor Biopharma Inc. will continue its operations and development activities.
• The Reporting Persons may choose to exercise their warrants to acquire additional shares of Common Stock, subject to the beneficial ownership limitation.

Key Dates

Recommendation

The filing indicates a significant institutional investment, which is generally a positive signal for the company's long-term prospects. However, a Schedule 13G is a passive filing and does not provide new operational or financial performance data for Vor Biopharma. Without additional information on the company's fundamentals, pipeline progress, or market conditions, a 'hold' recommendation is prudent for existing investors, while potential new investors might consider this a positive indicator for further due diligence. The 9.99% beneficial ownership limit also suggests a passive, non-controlling interest, which limits immediate impact on company strategy.

Keywords

Vor Biopharma, VOR, Forbion Growth III, Schedule 13G, Beneficial Ownership, Warrants, Biopharma Investment, Institutional Investor, SEC Filing